Last reviewed · How we verify

NCT02986789

Continuous Non-Invasive SpHb and PVI Monitoring on Intra-Operative and Post-Surgical Clinical Outcomes

Terminated Results posted Last updated 12 November 2025
What this trial tests

trial testing In vivo SpHb and PVi Monitoring in Surgery in 43 participants. Terminated before completion.

Timeline
15 December 2016
Primary endpoint
31 August 2018
31 August 2018

Quick facts

Lead sponsorMasimo Corporation
StatusTerminated
Study typeINTERVENTIONAL
Allocationnon randomized
Designsingle group
Maskingnone
Primary purposeother
Enrollment43
Start date15 December 2016
Primary completion31 August 2018
Estimated completion31 August 2018

Drugs / interventions tested

Conditions studied

Sponsor

Masimo Corporation — full company profile →

Who can join

18 and older, any sex, with Surgery. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

The study evaluates the use of noninvasive hemoglobin with In Vivo feature and PVi monitoring using pulse-oximetry based technologies and their effect on the management of transfusion and infusion decisions and clinical outcomes for the surgical patient.

Publications & conference data

No peer-reviewed publications indexed yet for this trial.

Verify or expand the search:

Other recruiting trials for Surgery

Currently open trials in the same condition.

Other Masimo Corporation trials

Trials by the same sponsor.

Verify against primary sources

Data sources for this page

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT02986789.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing